Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer.
Esmo Open
Cardone, Claudia C; Martinelli, Erika E; Troiani, Teresa T; Sforza, Vincenzo V; Avallone, Antonio A; Nappi, Anna A; Montesarchio, Vincenzo V; Andreozzi, Francesca F; Biglietto, Maria M; Calabrese, Filomena F; Bordonaro, Roberto R; Cordio, Stefano S; Bregni, Giacomo G; Febbraro, Antonio A; Garcia-Carbonero, Rocio R; Feliu, Jaime J; Cervantes, Andrés A; Ciardiello, Fortunato F